pMHC Antibody Discovery

All of the advantages of human monoclonal antibodies with the ability to target intracellular proteins enabled by our revolutionary technology platform, Retained DisplayTM (ReD).

ReD: Targeting Intracellular Proteins

Existing antibody-based therapies such as bispecific antibodies and CAR-T cells target proteins expressed on the cell surface. Affinity’s ReD platform is enabling antibody-based therapeutics to be developed against a much broader range of targets including those that are expressed intracellularly. While antibodies cannot access the interior of the cell, Affinity’s scFvs can target the same antigen presentation pathway used by T-cells, where fragments of intracellular proteins are presented on the cell surface. Affinity’s scFvs will dramatically increase the approaches to treating solid tumors, persistent viral infections, and certain autoimmune diseases.

Learn more about our technology
Innovation feature

COVID-19 ipsum dolor sit amet, consectetur afiplsicing elit

Learn more

Latest news

Affinity’s COVID-19 antibodies ready for manufacture for clinical trials

30 July 2020, Melbourne, Australia Melbourne-based Affinity Biosciences Pty Ltd (Affinity) has lodged a pre-publication submission to the scientific…

Read More

Affinity discovers potent SARS-CoV-2 antibodies

Melbourne-based Affinity Biosciences Pty Ltd (Affinity), a privately held company focused on antibody discovery for cancer therapeutics, today…

Read More

Affinity part of COVID-19 ‘biologics’ medicine consortium awarded grant funding from MRFF

On 2 June 2020 the Australian government announced that Melbourne-based Affinity Biosciences Pty Ltd (Affinity) would receive funding from the…

Read More

Our research and development partners